jRCT2051240252招募中不适用
A Randomized, Single-Center, Double-Blind, Placebo-Controlled, Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of SCO-240 in Healthy Adult Subjects
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 32
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Other
- 盲法
- Double Blind
入排标准
- 年龄范围
- 18age old over 至 65age old under（—）
- 性别
- Male
入选标准
- •Gender: Male
- •Age: Subjects are between 18 and 65 years, inclusive, at the time of informed consent
- •Weight at screening: >=50 kg, body mass index (BMI) >=18.5 kg/m2 and =<25.0 kg/m2
排除标准
- •Subjects who have a present illness such as cardiovascular disease, central nervous system disease, gastrointestinal disease, hematopoietic disease, renal failure, metabolic or endocrine disorder, serious allergy, asthma, hypoxemia, hypertension, convulsion or allergic rash.
结局指标
主要结局
-
Safety and pharmacokinetics
次要结局
未报告次要终点
研究者
相似试验
招募中
1 期
A trial to learn about a study drug (STAR-0215) in adults with hereditary angioedemaCTIS2022-502953-32-01Astria Therapeutics Inc.53
已完成
1 期
Phase 1, Single and Multiple Topically Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of M119102 in Healthy Adult Subjects.Alopecia AreataJPRN-jRCT2071220006Tomoyuki Nishiura16
进行中（未招募）
1 期
Study to Evaluate the Effect of GBT440 in Pediatrics With Sickle Cell DiseaseSickle Cell DiseaseEUCTR2016-004209-15-GBGlobal Blood Therapeutics, Inc.148
已完成
2 期
Study to Evaluate the Effect of GBT440 in Pediatrics With Sickle Cell DiseaseSickle Cell, Anemia, Hemolytic, Congenital, Hematologic DiseasesSickle Cell DiseaseLBCTR2019090195Global Blood Therapeutics Inc.38
进行中（未招募）
1 期
A study to find out the safety, tolerability and processing of RO7204239 by the body, the effect of RO7204239 on the body in participants with high body weightHealthy volunteersISRCTN10993304F. Hoffmann-La Roche Ltd36